Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals, has received approval from the National Medical Products Administration for a clinical trial of its HRS-9821 inhalation powder. This approval marks a significant step for the company as it aims to advance its product pipeline in treating chronic obstructive pulmonary conditions, potentially strengthening its position in the pharmaceutical market.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$78.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, specializing in the development and production of innovative drugs. The company focuses on providing treatments for various medical conditions, with a strong emphasis on research and development in the pharmaceutical industry.
Average Trading Volume: 5,741,310
Current Market Cap: HK$380.5B
Learn more about 1276 stock on TipRanks’ Stock Analysis page.